"Siperstein Dermatology Group offers an array of medical procedures and skin services from general dermatology, to cosmetic procedures, anti-aging and skin-rejuvenating treatments. We are board-certified dermatologists, physician assistants, and licensed aestheticians who strive to create a personal experience for each and every patient while tailoring a custom plan of action to meet the patients’ medical and aesthetic goals. Our team is uniquely trained to analyze your skin and this training enables our providers to see any potential skin problems and diagnose a variety of skin conditions ranging from minor to life-threatening."

During the past decade, Siperstein Dermatology Group conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 3 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 3 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Siperstein Dermatology Group" #1 collaborator was "Allergan" with 1 trials as a collaborator and "University of Miami" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Siperstein Dermatology Group" are "Alopecia Areata" (3 trials), "Atrophic Scar" (1 trials), "Bateman's Purpura" (1 trials), "Infraorbital Hollows" (1 trials) and "Senile Purpura" (1 trials). Many other conditions were trialed in "Siperstein Dermatology Group" in a lesser frequency.

Most popular intervention types in "Siperstein Dermatology Group" are "Device" (3 trials), "Drug" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Allergan Vollure" (1 trials), "Broad Band Light (BBL)" (1 trials), "CTP-543" (1 trials), "CTP-543 matching placebo" (1 trials) and "Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Siperstein Dermatology Group" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Siperstein Dermatology Group". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Siperstein Dermatology Group, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Siperstein Dermatology Group, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".